Target intelligence / Profile preview

Mitogen-activated protein kinase 11 (MAPK11)

Target
MAPK11
Molecular classification
Enzyme, Kinase, Protein kinase, Serine/threonine-protein kinase, Mitogen-activated protein kinase
01

Overview

Mitogen-activated protein kinase 11 (MAPK11), commonly known as p38β, is a serine/threonine kinase belonging to the p38 mitogen-activated protein kinase (MAPK) family. It plays a critical role in cellular responses to environmental stress, physical stimuli, and pro-inflammatory cytokines by phosphorylating downstream transcription factors and kinases. MAPK11 is ubiquitously expressed, with particularly high levels in the heart, brain, and skeletal muscle, where it regulates processes such as cell differentiation, apoptosis, and myogenesis. Dysregulation of MAPK11 signaling is implicated in various pathological conditions, including chronic inflammatory disorders, autoimmune diseases, neurodegenerative conditions like Huntington's disease, and several types of cancer.

Therapeutic targeting of MAPK11 has primarily focused on small-molecule inhibitors, many of which dual-target both the alpha (MAPK14) and beta isoforms due to high sequence similarity. While several p38 inhibitors, such as losmapimod and ralimetinib, have entered clinical trials for inflammatory diseases, neuropathic pain, and oncology, their clinical development has faced significant hurdles. Notable challenges include class-wide safety concerns such as hepatotoxicity, skin rashes, and central nervous system toxicities, alongside potential efficacy limitations stemming from functional redundancy with other p38 isoforms.

Other names
p38 betap38βMitogen-activated protein kinase p38 betap38-2SAPK2SAPK2BPRKM11Stress-activated protein kinase 2b
02

Mechanism of action

Inhibitor of p38 mitogen-activated protein kinase (MAPK), acting via ATP-competitive or allosteric binding to block downstream phosphorylation cascades.

03

Biological functions

Signal transductionCell differentiationApoptosisCell proliferationInflammatory responseGene expression regulationProtein turnoverMyogenesis
04

Disease associations

InflammationCancerNeurodegenerative diseaseCardiovascular diseaseAutoimmune diseaseNeuropathic painMuscular dystrophy
05

Safety considerations

HepatotoxicityInhibition of myogenesis and muscle regenerationCardiovascular toxicitySkin rash and dermatological toxicityCentral nervous system inflammatory syndromeLack of clinical efficacy due to redundancy with p38α (MAPK14)
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

Phospho-MK2Phospho-p38C-reactive proteinInterleukin-6Tumor necrosis factor-alphaSTK11 expression

Beyond the preview

Go deeper on Mitogen-activated protein kinase 11 (MAPK11).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitogen-activated protein kinase 11 (MAPK11).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call